Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.070
-0.960 (-31.68%)
At close: Oct 14, 2026, 4:00 PM EDT
1.940
-0.130 (-6.28%)
After-hours: Oct 14, 2026, 7:59 PM EDT
Alaunos Therapeutics Employees
Alaunos Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Alaunos Therapeutics the 44,276th largest employer in the world and 7,645th in the United States.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,000
Profits / Employee
-$4,116,000
Market Cap
5.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2023 | 1 | -33 | -97.06% | 1 | 0 |
| Dec 31, 2022 | 34 | -7 | -17.07% | 34 | 0 |
| Dec 31, 2021 | 41 | -65 | -61.32% | 41 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| CollPlant Biotechnologies | 39 |
| Bolt Biotherapeutics | 23 |
| Moleculin Biotech | 17 |
| CalciMedica | 15 |
| Soligenix | 14 |
| CNS Pharmaceuticals | 8 |
| Aprea Therapeutics | 8 |
TCRT News
- 1 day ago - Alaunos Therapeutics announces completion of Velaris acquisition - TheFly
- 1 day ago - Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics - GlobeNewsWire
- 1 day ago - Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. - PRNewsWire
- 26 days ago - Alaunos Therapeutics prices 380,469 shares at $1.46 in registered direct offer - TheFly
- 26 days ago - Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules - GlobeNewsWire
- 2 months ago - Alaunos Therapeutics Quarterly report: Q2 2026 - Filings
- 4 months ago - Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies - TheFly
- 4 months ago - Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies - GlobeNewsWire